



Biodegradable Formulations for Ocular Drug Delivery

Guest Editors:

Dr. Irene Bravo-Osuna

Innovation, Therapy and
Pharmaceutical Development in
Ophthalmology (InnOftal)
Research Group, UCM 920415,
Department of Pharmaceutics
and Food Technology, Faculty of
Pharmacy, Complutense
University of Madrid, Plaza
Ramón y Cajal, s/n, 28040 Madrid,
Spain

Dr. María Jesús Rodrigo Sanjuán

1. Department of
Ophthalmology, Miguel Servet
University Hospital, 50009
Zaragoza, Spain
2. Miguel Servet Ophthalmology
Research Group (GIMSO), Aragon
Health Research Institute (IIS
Aragon), University of Zaragoza,
50009 Zaragoza, Spain

Message from the Guest Editors

Dear Colleagues,

The treatment of ocular pathology is challenging. It is necessary to reach the target cell and maintain effective concentrations at the site of action. Drug penetration, drug metabolism and cell–drug interactions are influenced by the surrounding cellular microenvironment and the pathological stage. There is currently a demand to develop ophthalmic formulations based on personalised medicine and focussed on the individual needs of each patient. In addition, there is a search for new formulations that minimise iatrogenesis, patient discomfort and costs. This Special Issue is open to original research articles, review articles or mini-reviews in this field covering technological, methodological, pharmacological (in vitro, ex vivo and in vivo) or biochemical approaches to biodegradable ophthalmic formulations for the treatment of ocular pathology, as well as for a potential application for early diagnosis.

Deadline for manuscript
submissions:

closed (30 June 2023)





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
[@MDPIpharma](https://twitter.com/MDPIpharma)